2m 2m 2m 2m 2m 2m 2m
- $4.1MMarket Cap
- -100.00%1-Year Change
- BiotechnologyIndustry
PROPANC BIOPHRM (PPCB)
Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Propanc Biopharma is pursuing a strategic initiative to acquire Digital Asset Treasury (DAT) companies trading below their market cap to net asset value, aiming to diversify its asset base and create shareholder value.
11/04/2025, 7:00 AM • GlobeNewswire
Propanc Biopharma secured a strategic financing agreement with Hexstone Capital for up to $100 million, involving convertible preferred stock and warrants to support clinical pipeline development and digital asset treasury strategy.
10/15/2025, 5:45 PM • GlobeNewswire
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
Propanc Biopharma successfully closed a public offering of 1,000,000 shares at $4.00 per share, raising $4 Million and commencing trading on the Nasdaq Capital Market under the ticker PPCB.
08/19/2025, 8:30 AM • Benzinga
Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering
Propanc Biopharma announced a public offering of 1 million shares at $4.00 per share, expecting to raise approximately $4 million. The company will use proceeds for working capital and has received approval to list on Nasdaq Capital Market.
08/14/2025, 11:00 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/03/2026
Company Profile
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
Key Executives
- James Nathanielsz
- Klaus Kutz
- Jeannine Zimmerman
Current Ownership Distribution
- Insiders24.3M (100.00%)
- Institutions0 (0.00%)
- Mutual Funds0 (0.00%)
- Other0 (0.00%)